Nervous System News and Research

Latest Nervous System News and Research

Study needed to identify most effective exercise to improve balance among older people

Good balance and mobility are essential to help you perform most activities involved in every-day life, as well as many recreational pursuits. Keeping your balance is a complex task, involving the co-ordination between a person's muscles and sensors which detect balance and are part of the nervous system.

9 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

Study reveals need for defining optimal amount of iron in infant formula

A 10-year follow-up study examining iron-fortified vs. low-iron infant formula suggests that infants with high hemoglobin levels who received iron fortified infant formula have poorer long-term developmental outcomes.

9 Nov 2011

Inhaling low levels of CO reduces impact of environmental stress

According to scientists, carbon monoxide (CO), a tasteless, colorless and odorless gas, is not only a danger to the environment but also highly toxic to human beings. Found in the exhaust of vehicles and generators, CO has been dubbed the "silent killer" because excessive inhalation is lethal, poisoning the nervous system and heart.

9 Nov 2011

QRxPharma receives FDA written acceptance for review of MoxDuo IR NDA

QRxPharma Limited announced today it received written acceptance from the United States Food and Drug Administration (FDA) for review of the MoxDuo IR New Drug Application (NDA) filed earlier this year.

9 Nov 2011

Omeros third quarter net loss decreases to $6.5 million

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2011.

9 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

Study: Genes that are active in brain are transcribed with special mechanism

Knowledge about the development of the nervous system is of the greatest importance for us to understand the function of the brain and brain disorders. Researchers at Uppsala University have examined the key step when genes are read and found that genes that are active in the brain are transcribed with a special mechanism.

8 Nov 2011

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.

8 Nov 2011

A person's stroke risk profile may help identify future cognitive problems

A new study shows a person's stroke risk profile, which includes high blood pressure, smoking, and diabetes, may also be helpful in predicting whether a person will develop memory and thinking problems later in the life.

8 Nov 2011

Brain plays a key role in regulating glucose metabolism in humans

Researchers at Albert Einstein College of Medicine of Yeshiva University have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.

7 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

New data from Novartis' ACZ885 Phase III study on SJIA

Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885.

7 Nov 2011

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Abbott today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively.

7 Nov 2011

Vitamin D supplementation benefits people with lupus

The first study to report the effects vitamin D has on the immune system of people with lupus was reported this week a the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Biologics reduce fatigue in people with RA

Treatment with a biologic agent reduces fatigue in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

IFNa-kinoid shows promise against lupus

The first study to show results using active immunotherapy against the signaling protein interferon alpha in the treatment of lupus will be presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Human Genome Sciences, Inc. announced today that several abstracts related to BENLYSTA (belimumab) and systemic lupus erythematosus will be presented at the annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals, being held in Chicago, IL from November 4 to November 9, 2011.

5 Nov 2011